Structure and metabolic fate of triacylglycerol- and phospholipid-rich particles of commercial parenteral fat emulsions
- PMID: 9918062
- DOI: 10.1016/s0899-9007(98)00130-0
Structure and metabolic fate of triacylglycerol- and phospholipid-rich particles of commercial parenteral fat emulsions
Abstract
The lipid emulsions used in parenteral nutrition are constituted of particles rich in triacylglycerols (TAG) called artificial chylomicrons (200-500 nm in diameter; monolayer of phospholipids [PL] enveloping a TAG core) and PL-rich particles called liposomes (diameter inferior to 80 nm; bilayer of PL around an aqueous phase), which represent the excess emulsifier. Introduced into the circulation, the two populations of particles come into contact with circulating lipoproteins and cell membranes and experience the same overall fate: exchanges and transfers of lipids and apolipoproteins, enzymatic hydrolysis of TAG and PL, and internalization by different tissues. The relative importance of these different metabolic processes varies depending on the type of particle. The artificial chylomicrons undergo a hydrolysis of their TAG by lipoprotein lipase, with a release of fatty acids and formation of smaller particles of remnants, which are rapidly removed by the liver. In delivering fatty acids to the tissue, artificial chylomicrons fulfill an energy transport function similar to the natural chylomicrons. The liposomes hold little energy interest, and they also have deleterious effects when infused in excess. They inhibit the lipolysis of artificial chylomicrons and, by actively capturing endogenous cholesterol, they stimulate tissue cholesterogenesis and accumulate in the blood as lipoprotein-X, a long-lived abnormal lipoprotein. To limit as much as possible the metabolic perturbations due to the intravenous administration of exogenous PL, the emulsion has to be infused at a low rate, and should contain the minimal amount of excess PL.
Similar articles
-
Effects of intravenous infusions of commercial fat emulsions (Intralipid 10 or 20%) on rat plasma lipoproteins: phospholipids in excess are the main precursors of lipoprotein-X-like particles.Biochim Biophys Acta. 1990 Nov 12;1047(2):121-30. doi: 10.1016/0005-2760(90)90037-x. Biochim Biophys Acta. 1990. PMID: 2248969
-
Phospholipid-rich particles in commercial parenteral fat emulsions. An overview.Prog Lipid Res. 1996;35(2):133-53. doi: 10.1016/0163-7827(96)00001-x. Prog Lipid Res. 1996. PMID: 8944224 Review.
-
Clinical significance of transfer of apolipoproteins between triacylglycerol-rich particles in lipid emulsions and plasma lipoproteins.Nutrition. 1994 May-Jun;10(3):252-4. Nutrition. 1994. PMID: 7919678 Review.
-
Lipid composition and structure of commercial parenteral emulsions.Biochim Biophys Acta. 1994 Jul 14;1213(2):149-58. doi: 10.1016/0005-2760(94)90021-3. Biochim Biophys Acta. 1994. PMID: 8025125
-
Intralipid 10%: physicochemical characterization.Nutrition. 2001 Nov-Dec;17(11-12):930-3. doi: 10.1016/s0899-9007(01)00667-0. Nutrition. 2001. PMID: 11744343
Cited by
-
Composition and Functionality of Lipid Emulsions in Parenteral Nutrition: Examining Evidence in Clinical Applications.Front Pharmacol. 2020 Apr 29;11:506. doi: 10.3389/fphar.2020.00506. eCollection 2020. Front Pharmacol. 2020. PMID: 32410990 Free PMC article. Review.
-
Injectable lipid emulsions-advancements, opportunities and challenges.AAPS PharmSciTech. 2010 Dec;11(4):1526-40. doi: 10.1208/s12249-010-9526-5. Epub 2010 Oct 26. AAPS PharmSciTech. 2010. PMID: 20976577 Free PMC article. Review.
-
Premorbid obesity, but not nutrition, prevents critical illness-induced muscle wasting and weakness.J Cachexia Sarcopenia Muscle. 2017 Feb;8(1):89-101. doi: 10.1002/jcsm.12131. Epub 2016 Jul 20. J Cachexia Sarcopenia Muscle. 2017. PMID: 27897405 Free PMC article.
-
Intravenous Fat Emulsion Formulations for the Adult and Pediatric Patient: Understanding the Differences.Nutr Clin Pract. 2016 Oct;31(5):596-609. doi: 10.1177/0884533616662996. Epub 2016 Aug 16. Nutr Clin Pract. 2016. PMID: 27533942 Free PMC article. Review.
-
Effects of propofol and its formulation components on macrophages and neutrophils in obese and lean animals.Pharmacol Res Perspect. 2021 Oct;9(5):e00873. doi: 10.1002/prp2.873. Pharmacol Res Perspect. 2021. PMID: 34632734 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources